市場調查報告書
商品編碼
1371981
2030 年 3D 細胞培養支架市場預測:按類型、用途和地區分類的全球分析3D Cell Culture Scaffold Market Forecasts to 2030 - Global Analysis By Type (Fiber, Hydrogel, Decellularized Scaffolds, Synthetic Polymers and Other Types), Application and By Geography |
根據 Stratistics MRC 的數據,全球 3D 細胞培養支架市場預計在預測期內將以 17.0% 的年複合成長率成長。
涉及3D(3D)細胞培養支架或基質的製造、銷售和應用的全球產業被稱為「3D細胞培養支架市場」。這些支架為細胞在三個維度上的發育、增殖和分化提供了有利的環境,與活體組織和器官中的條件非常相似。該市場包括各種合成聚合物、去細胞組織、水凝膠以及用於製造這些 3D 結構的其他材料和技術。
根據美國國立衛生研究院的數據,2020 年各種生物工程技術的總投資達 5,646 美元,高於 2019 年的 5,091 美元。根據美國衛生資源與服務管理局網站「organdonor.gov」顯示,截至2021年10月,2020年美國等待器官移植的患者人數為107,103人。
人們對再生醫學和組織工程應用的興趣日益濃厚,為 3D 細胞培養支架促進生產用於移植的功能性組織和器官提供了機會。此外,藥物開發中對更可靠的體外模型的需求不斷成長,並且有機會建立更好的預測工具來測試藥物功效和安全性。
由於支架材料和技術多種多樣,很難為使用 3D 細胞培養支架的研究創建標準化方案。然而,由於它們比傳統的 2D 培養技術更昂貴,因此3D 細胞培養支架和相關技術可能不會被廣泛使用,特別是在資源有限的環境中。
隨著 3D 細胞培養技術(包括基於支架的方法)的不斷發展,體外細胞模型的準確性和生理有效性正在提高,從而增加了對支架的需求。此外,在癌症研究和藥物試驗中,基於支架的 3D 細胞培養模型可以實現更複雜、更真實的腫瘤模型,從而帶來更好的治療方法。
我們的 3D 細胞培養支架業務受到法規延誤和成本增加的影響,特別是在用於藥物測試和安全評估時。複雜的法規可能適用於 3D 細胞培養模型的使用,特別是在藥物開發和毒性測試中。遵守這些法規並獲得必要的核准可能需要大量的資源和時間。
由於全球供應線中斷,疫情影響了製造 3D 細胞培養支架的基本材料和組件的供應。結果,製造商遭遇了延誤和成本增加。由於經濟不確定性,疫情期間研發部門的預算限制可能影響了 3D 細胞培養支架的投資。
預計合成聚合物領域在預測期內將佔據最大佔有率。合成聚合物領域是 3D 細胞培養支架市場的關鍵結構要素,提供各種具有特定品質的工程材料,用於開發 3D 細胞培養環境。此外,合成聚合物由於其多功能性和生物相容性而非常重要,可以為個體化治療創造複雜的細胞培養條件。合成聚合物透過促進功能組織和器官的發育,為推進再生醫學提供了機會。
預計生物製藥領域的年複合成長率最高。生物製藥公司使用 3D 細胞培養支架來加速藥物研發發現和開發過程。這些支架能夠更準確地模擬體內情況,並能夠更準確地評估候選藥物的功效和安全性。此外,它對於創建生理上準確的細胞模型以用於毒性、癌症和標靶藥物設計的研究至關重要。 3D 細胞培養支架市場正在幫助生物製藥公司追求個人化醫療,讓他們可以根據個別患者的反應來客製化藥物。
亞太地區所佔比例最高。隨著該地區發展成為醫療旅遊和高科技醫療服務中心,依賴 3D 細胞培養模型的精準醫療和組織再生變得越來越重要。此外,中國和印度等國家的強勁經濟成長正在推動醫療保健和生命科學領域的投資,從而推動對尖端細胞培養技術的需求。
亞太地區預計將快速成長。由於該地區心血管疾病的流行,血管生物學研究和 3D 細胞培養支架的製造正在進行中,以更好地了解這些疾病並制定治療方法。此外,亞太地區的製藥部門正在使用 3D 細胞培養模型來測試心血管療法並評估它們如何影響血管生物學,以幫助藥物開發。
According to Stratistics MRC, the Global 3D Cell Culture Scaffold Market is expected to grow at a CAGR of 17.0% during the forecast period. The global industry for the manufacture, sale, and application of three-dimensional (3D) cell culture scaffolds or matrices is known as the "3D Cell Culture Scaffold Market." These scaffolds offer an environment that is favorable to cell development, proliferation, and differentiation in three dimensions and closely resembles the circumstances found in living tissues and organs. The market includes a wide range of synthetic polymers, decellularized tissues, hydrogels, and other materials and technologies that are used to produce these 3D structures.
According to the National Institute of Health, in 2020, the total investment in various bio engineering technologies amounted to USD 5,646, an increase from USD 5,091 in 2019. According to the organdonor.gov website of the United States Health Resources and Services Administration, in October 2021, 107,103 patients were on the national organ transplant waiting list in the year 2020.
Opportunities for 3D cell culture scaffolds to promote the production of functional tissues and organs for transplantation are offered by the growing interest in regenerative medicine and tissue engineering applications. Additionally, the market acquires from the growing demand for more reliable in vitro models in drug development, providing the chance to build better prediction tools for testing medication efficacy and safety.
Due to the wide range of scaffold materials and technologies available, creating standardized protocols for 3D cell culture scaffold-based research can be difficult. However, they can be more expensive than conventional 2D culture techniques, 3D cell culture scaffolds and related technologies may not be as widely used, especially in environments with limited resources.
The accuracy and physiological relevance of in vitro cell models are being improved by ongoing developments in 3D cell culture techniques, including scaffold-based approaches, which are increasing the demand for scaffolds. Additionally, for cancer research and medication testing, 3D cell culture models using scaffolds allow for more complicated and realistic tumor models, which leads to better therapeutic approaches.
Regulations can cause delays and higher costs in the 3D cell culture scaffold business, particularly when utilized for drug testing and safety evaluations. Complex regulatory regulations may apply to the use of 3D cell culture models, particularly in drug development and toxicity testing. It can take a lot of resources and time to comply with these rules and get the required approvals.
The pandemic affected the availability of essential materials and components needed to produce 3D cell culture scaffolds by disrupting global supply lines. Manufacturers experienced delays and higher expenses as a result. Budget restrictions in the research and development divisions during the pandemic were caused by economic uncertainty, which might have had an impact on investments in 3D cell culture scaffolds.
Synthetic Polymers segment is expected to hold the largest share over the forecast period. A crucial component of the market for 3D cell culture scaffolds, the synthetic polymer sector provides an extensive range of designed materials with specific qualities for developing three-dimensional cell culture settings. Additionally, in order to create complex cell culture conditions for personalized treatment, synthetic polymers are crucial because of their versatility and biocompatibility. They provide the chance for advancements in regenerative medicine by facilitating the development of functioning tissues and organs.
Biopharmaceutical segment is expected to have the highest CAGR. 3D cell culture scaffolds are used by biopharmaceutical businesses to accelerate the drug discovery and development process. These scaffolds offer a more exact approximation of in vivo circumstances, enabling more accurate efficacy and safety assessments of drug candidates. Additionally, they are crucial in the production of physiologically accurate cell models for inquiries on toxicity, cancer, and the design of targeted medicines. The market for 3D cell culture scaffolds aids biopharmaceutical companies in the pursuit of personalized medicine by enabling them to customize medicines based on individual patient responses.
The largest share was held by the Asia-Pacific area. Precision medicine and tissue regeneration, which rely on 3D cell culture models, are becoming more and more important as the area develops as a center for medical tourism and high-tech healthcare services. Additionally, investments in healthcare and life sciences are being fueled by the robust economic growth of nations like China and India, which is raising the demand for cutting-edge cell culture technologies.
Asia Pacific region is expected to grow rapidly. The prevalence of cardiovascular disorders in the area has prompted an examination of vascular biology and the creation of 3D cell culture scaffold in an effort to better understand these illnesses and create therapeutic remedies. Moreover, the Asia Pacific region's pharmaceutical sector uses 3D cell culture models to test cardiovascular medications and assess how they affect vascular biology, which helps in drug development.
Some of the key players in 3D Cell Culture Scaffold Market include: 3D Biotek, Corning Incorporated, Greiner Bio-One, InSphero AG, Lonza Group, Merck KGaA, N3d Bioscience, Nanofiber Solutions, Reprocell Incorporated, Synthecon Incorporated, TARA Biosystems and Thermo Fisher Scientific.
In October 2023, Thermo Fisher expands US manufacturing plant to support biologics. The US-based biotechnology and medical equipment company has added multiple biologic manufacturing facilities to accommodate a growing demand for these therapies.
In October 2023, Thermo Fisher Scientific, the world leader in serving science, expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders.